In a study of ovarian and osteosarcoma cancer cells appearing July 19 in Cell Systems, Yaffe Lab researchers find that timing and dosage of DNA-damaging drugs are key whether cancer cells die or enter senescence. The study has implications for how a class of cancer drugs called MEK inhibitors are used in combination with chemotherapy.